In patients with type 2 diabetes, SGLT2 inhibitors decrease the levels of proinflammatory cytokines (TNF-α, IL-6, and IL-1β) and attenuate the activity of NLRP3 inflammasome [17,18,31]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.